{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:20:37Z","timestamp":1791285637141,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23EY03298"],"award-info":[{"award-number":["K23EY03298"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001855"],"award-info":[{"award-number":["UL1TR001855"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112457","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T17:01:12Z","timestamp":1757091672000},"page":"112457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intravitreal anti-VEGF therapy and risk of limb complications in individuals with diabetic eye disease"],"prefix":"10.1016","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-6391","authenticated-orcid":false,"given":"Alexander T.","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0233-2044","authenticated-orcid":false,"given":"Ivan Y.","family":"Luu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4448-678X","authenticated-orcid":false,"given":"Forest","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze-Woei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9612-5697","authenticated-orcid":false,"given":"Brian C.","family":"Toy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2025.112457_b0005","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaophthalmol.2022.0052","article-title":"Trends in prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among medicare part B fee-for-service beneficiaries","volume":"140","author":"Lundeen","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112457_b0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2337\/dc22-1834","article-title":"Trends in the Prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among commercially insured adults aged <65 years","volume":"46","author":"Lundeen","year":"2023","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.diabres.2025.112457_b0015","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2025.112457_b0020","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"2023","author":"Virgili","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.diabres.2025.112457_b0025","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2012.07.058","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American academy of ophthalmology","volume":"119","author":"Ho","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.diabres.2025.112457_b0030","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamaophthalmol.2023.2098","article-title":"Systemic adverse events among patients with diabetes treated with intravitreal anti\u2013vascular endothelial growth factor injections","volume":"141","author":"Zafar","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112457_b0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3390\/jpm13030544","article-title":"The association of intravitreal injections of different anti-vascular endothelial growth factor with systemic outcomes in diabetic patients","volume":"13","author":"Kang","year":"2023","journal-title":"J Pers Med"},{"issue":"12","key":"10.1016\/j.diabres.2025.112457_b0040","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.diabres.2025.112457_b0045","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2023.10578","article-title":"Diabetic foot ulcers","volume":"330","author":"Armstrong","year":"2023","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2025.112457_b0060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/diacare.25.3.471","article-title":"Diabetes-related morbidity and mortality in a national sample of U.S. elders","volume":"25","author":"Bertoni","year":"2002","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2025.112457_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175270","article-title":"Association between diabetic foot ulcer and diabetic retinopathy","volume":"12","author":"Hwang","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.diabres.2025.112457_b0070","doi-asserted-by":"crossref","first-page":"e3605","DOI":"10.1002\/dmrr.3605","article-title":"Diabetic retinopathy relates to the incidence of foot ulcers and amputations in type 2 diabetes","volume":"39","author":"Borderie","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0075","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2337\/dci22-0043","article-title":"Etiology, epidemiology, and disparities in the burden of diabetic foot ulcers","volume":"46","author":"McDermott","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2025.112457_b0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.diabres.2025.112457_b0085","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ophtha.2018.09.040","article-title":"Risk of systemic adverse events associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice","volume":"126","author":"Maloney","year":"2019","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.diabres.2025.112457_b0090","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/ndt\/gfac305","article-title":"A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes","volume":"38","author":"Lees","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.diabres.2025.112457_b0095","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"7","key":"10.1016\/j.diabres.2025.112457_b0100","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jamaophthalmol.2024.1844","article-title":"Progression to pars plana vitrectomy in patients with proliferative diabetic retinopathy","volume":"142","author":"Alsoudi","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jvs.2023.02.014","article-title":"A comparison of endovascular repair to medical management for acute vs subacute uncomplicated type B aortic dissections","volume":"78","author":"Muller","year":"2023","journal-title":"J Vasc Surg"},{"issue":"4","key":"10.1016\/j.diabres.2025.112457_b0110","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.diabres.2025.112457_b0115","doi-asserted-by":"crossref","DOI":"10.2337\/dc25-0292","article-title":"Differential effect of GLP-1 receptor agonists and SGLT2 inhibitors on lower-extremity amputation outcomes in type 2 diabetes: a nationwide retrospective cohort study","author":"Hong","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2025.112457_b0120","doi-asserted-by":"crossref","DOI":"10.2196\/18542","article-title":"Model-based algorithms for detecting peripheral artery disease using administrative data from an electronic health record data system: algorithm development study","volume":"8","author":"Weissler","year":"2020","journal-title":"JMIR Med Inform"},{"issue":"3","key":"10.1016\/j.diabres.2025.112457_b0125","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0801","article-title":"Foot and ankle care by podiatrists and amputations in patients with diabetes and kidney failure","volume":"7","author":"Tan","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.diabres.2025.112457_b0130","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jvscit.2022.10.003","article-title":"Deriving international classification of diseases, 9th and 10th revision, codes for identifying and following up patients with diabetic lower extremity ulcers","volume":"8","author":"Fowler","year":"2022","journal-title":"J Vasc Surg Cases Innov Tech"},{"issue":"2","key":"10.1016\/j.diabres.2025.112457_b0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00125-022-05845-9","article-title":"Global trends in the incidence of hospital admissions for diabetes-related foot disease and amputations: a review of national rates in the 21st century","volume":"66","author":"Lazzarini","year":"2023","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/dc21-1596","article-title":"Foot ulcer and risk of lower limb amputation or death in people with diabetes: a national population-based retrospective cohort study","volume":"45","author":"Chamberlain","year":"2022","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2025.112457_b0145","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00125-004-1463-y","article-title":"The diabetic foot: from art to science. The 18th Camillo Golgi lecture","volume":"47","author":"Boulton","year":"2004","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.diabres.2025.112457_b0150","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2337\/dc20-0586","article-title":"National and state-level trends in nontraumatic lower-extremity amputation among U.S. medicare beneficiaries with diabetes, 2000\u20132017","volume":"43","author":"Harding","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112457_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112331","article-title":"Trends of lower-limb complications in patients with type 2 diabetes mellitus during the COVID-19 pandemic","volume":"226","author":"Luu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13047-020-00383-2","article-title":"Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer","volume":"13","author":"Armstrong","year":"2020","journal-title":"J Foot Ankle Res"},{"issue":"3","key":"10.1016\/j.diabres.2025.112457_b0165","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2337\/dc13-2176","article-title":"Burden of diabetic foot ulcers for medicare and private insurers","volume":"37","author":"Rice","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2025.112457_b0170","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jss.2008.04.023","article-title":"The role of vascular endothelial growth factor in wound healing","volume":"153","author":"Bao","year":"2009","journal-title":"J Surg Res"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0175","first-page":"63","article-title":"Anti-VEGF agents and the risk of arteriothrombotic events","volume":"7","author":"Zarbin","year":"2018","journal-title":"Asia-Pacif J Ophthalmol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112457_b0180","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/S0002-9440(10)63754-6","article-title":"Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells","volume":"164","author":"Galiano","year":"2004","journal-title":"Am J Pathol"},{"issue":"16","key":"10.1016\/j.diabres.2025.112457_b0185","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jnci\/djm086","article-title":"Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab","volume":"99","author":"Scappaticci","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.diabres.2025.112457_b0190","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/aos.12604","article-title":"Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial","volume":"93","author":"Zehetner","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112457_b0195","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/IAE.0000000000002004","article-title":"Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema","volume":"38","author":"Hirano","year":"2018","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.diabres.2025.112457_b0200","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1111\/j.1755-3768.2011.02240.x","article-title":"Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab","volume":"90","author":"Carneiro","year":"2012","journal-title":"Acta Ophthalmol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:22:24Z","timestamp":1764080544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725004711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"alternative-id":["S0168822725004711"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112457","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal anti-VEGF therapy and risk of limb complications in individuals with diabetic eye disease","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112457"}}